JULY 10, 2024
Orexo AB´s sustainability work ranked among top 5% by EcoVadis
News & Insights
JULY 8, 2024
Invitation to presentation of the Q2 Interim Report on July 17 at 2 pm CET
JULY 4, 2024
Meet our people: Orexo's scientist Jonas Sävmarker on being curious and innovating for patients
A commercial stage pharmaceutical company with three revenue generating pharmaceutical products
AmorphOX® - a world-class powder-based drug delivery technology, leading to a new wave of a both small and large molecule pharmaceuticals.
Development pipeline targeting large medical needs
ESG sustainable investing
Read all documents related to the refinancing of the existing bond - MARCH 2024
Key financial figures
Group net revenue
619 MSEK
Last Twelve Months, Q223-Q124
Group EBITDA
24 MSEK
Last Twelve Months, Q223-Q124
US Commercial segment EBIT
146 MSEK
Last Twelve Months, Q223-Q124
Cash position
198 MSEK
Q124